ALRN - Aileron Short-Term Debt to Capital
Aileron Therapeutics (ALRN) operates with high risk, as business success depends on medical test outcomes and the absence of adverse bodily reactions. The company is optimizing the supply of components for drug synthesis, which supports stable profits. Sales potential is significant due to high clinic demand for bone marrow protection, with the indicator standing at 0.00. The market capitalization trend is presented below.
Summary analytical data breakdowns for Aileron (ALRN)
The ratio of short-term liabilities with a maturity of over one year to equity measures liquidity risk and the company's dependence on debt financing, which, at a value of 0.00, reflects the current debt load of Aileron Therapeutics; analyzing the share of short-term loans in the company's capital allows for an assessment of the ability of ALRN to maintain the cost of ESG standards in oncology without compromising operational stability.